Cassie M. Lane

A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors

Johanna C. Bendell, Carla Kurkjian, Jeffrey R. Infante et al. · Investigational New Drugs · 2015 · 115 citations

Pharmacy, Oncology, Pharmacology +8

In Vitro Activity of TD-6424 against<i>Staphylococcus aureus</i>

John Pace, Kevin M. Krause, Deborah Johnston et al. · Antimicrobial Agents and Chemotherapy · 2003 · 108 citations · Full text

Medicine, Infectious Diseases, Pharmacology +15

Bevacizumab and everolimus in the treatment of patients with metastatic melanoma

John D. Hainsworth, Jeffrey R. Infante, David R. Spigel et al. · Cancer · 2010 · 76 citations

Pharmacy, Oncology, Pharmacotherapy +17

Paclitaxel/Carboplatin/Etoposide Versus Gemcitabine/Irinotecan in the First-Line Treatment of Patients With Carcinoma of Unknown Primary Site

John D. Hainsworth, David R. Spigel, Bobby L. Clark et al. · The Cancer Journal · 2010 · 66 citations

Medicine, Oncology, Pharmacology +11

Paclitaxel/Carboplatin plus Bevacizumab/Erlotinib in the First-Line Treatment of Patients with Carcinoma of Unknown Primary Site

John D. Hainsworth, David R. Spigel, Dana S. Thompson et al. · The Oncologist · 2009 · 61 citations · Full text

Medicine, Oncology, Pharmacology +15